Quarterly ResultAug 12, 2026, 09:36 AM
Monopar Q2 2026 Net Loss $(5.31)M; Operating Expenses Up 105%
AI Summary
Monopar Therapeutics reported a net loss of $(5.31) million for Q2 2026, widening from $(2.45) million in Q2 2025, as operating expenses surged by 105% to $6.64 million. For the first six months of 2026, the company incurred a net loss of $(9.21) million. Monopar, a clinical-stage biopharmaceutical company, has an accumulated deficit of approximately $98.7 million and has not generated revenue since inception, but expects current cash to fund operations through December 31, 2027.
Key Highlights
- Q2 2026 net loss was $(5.31) million, compared to $(2.45) million in Q2 2025.
- Operating expenses for Q2 2026 increased 105% to $6.64 million.
- Net loss for the six months ended June 30, 2026, was $(9.21) million.
- Operating expenses for the six months ended June 30, 2026, rose 84% to $11.87 million.
- Cash and cash equivalents stood at $52.76 million as of June 30, 2026.
- The company reported an accumulated deficit of approximately $98.7 million.
- Management expects current cash to fund operations through December 31, 2027.
- Basic and diluted EPS for Q2 2026 was $(0.62).
Price Impact
More from MNPR